BRAF and melanoma: Unlike ICB, the objective response rates (ORR) obtained with BRAF/MEKi, in BRAFV600-mutant AJCC stage IV-M1d melanoma are similar to patients without MBM, irrespective of whether the MBM are symptomatic.